
Pfizer Inc.Brand (Centrum)
Centrum
Centrum is a globally leading vitamin and mineral supplement brand under Pfizer Inc., specializing in comprehensive A to Zn formulations for different age groups and specific nutritional needs. With production facilities across multiple global regions and distribution in 123 countries, the brand achieved approximately $2 billion in sales in 2024. Backed by Pfizer's pharmaceutical expertise and research capabilities, Centrum maintains its market leadership through science-based formulations, pharmaceutical-grade quality standards, and extensive global reach. Strengths: Centrum's core strengths are its global leadership position in the vitamin and mineral supplement category with over 30% market share, pharmaceutical-grade manufacturing standards backed by Pfizer's quality systems, and extensive scientific research supporting product formulations with strong clinical evidence. Disadvantages: The brand faces challenges including intensifying competition from both pharmaceutical and consumer health companies, shifting consumer preferences towards specialized and alternative supplement formats, and evolving regulatory requirements across different global markets.Read MoreShow Less
Listed market data
PFE · NYSE · weeklyHistory →- Market cap
- $174 B
- Share price
- USD 30.67
- 1Y change
- +25.6%
- Recent change
- +0.5%
- Since first close
- ×36.6
- Revenue (TTM)
- $63.7 B
10-30 → 11-02
from 1972-06
Financial history
Full market history- 2026-11USD 30.67$174 B+3.7%
- 2026-10USD 29.58$169 B+3.7%
- 2026-09USD 28.52$163 B+0.2%
- 2026-08USD 28.46$162 B+13.8%
- 2026-07USD 25.01≈ $142 B+3.9%
- 2026-06USD 24.08≈ $137 B-8.0%
- 2026-05USD 26.18≈ $148 B-1.9%
- 2026-04USD 26.70≈ $151 B-4.9%
- 2026-03USD 28.08≈ $159 B+1.6%
- 2026-02USD 27.65≈ $157 B+4.6%
- 2026-01USD 26.44≈ $150 B+6.2%
- 2025-12USD 24.90≈ $141 B—
Ownership & Control
Shareholding as of 2026-06-30- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Manufacturer
- Insiders
- 0.10%
- Institutions
- 69.06%(3,673 holders)
- Free float
- 69.13%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines1- Pfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 Yearstikr.com2026-10-17
- Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?fool.com2026-10-16
- Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?finance.yahoo.com2026-10-16
- Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady247wallst.com2026-10-16
- What to Expect From Pfizer's Q3 2026 Earnings Reportbarchart.com2026-10-16
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $62.6 B | $7.8 B |
| 2024 | $63.6 B | $8 B |
| 2023 | $59.6 B | $2.1 B |
| 2022 | $101 B | $31.4 B |
| 2021 | $81.3 B | $22 B |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
New York City, New York, United States (Global Headquarters); China business center: Jing'an District, Shanghai
Founded
1849
Employees
88K+
Market cap
$174 B
Factories
10+
Presence
123+ Countries
Listing
NYSE: PFECategories
13 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $658 B
- Allergan Aesthetics· $521 B
- AbbVie Inc.· $521 B
- The Coca-Cola Company· $405 B
- F. Hoffmann-La Roche AG· $381 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: NYSE:PFE
